At the heart of this recognition is /skin-line™ technology – a first-of-its-kind formulation framework developed over more than a decade by Dr. Sharad, Founder and Master Formulator of NOTOXMD. Clinically tested and independently validated, /skin-line™ translates real-world healing patterns into daily skincare by optimising three critical factors: Dose, Delivery and Dermal Harmony. The result is visible, credible improvements in barrier function, hydration dynamics and balanced micro-inflammation, without compromising comfort or safety.
Widely regarded as a benchmark for scientific credibility and performance, the Skin Anarchy Beauty Awards are curated by leading dermatologists, aesthetic medicine experts and editorial beauty voices. A Top Picks accolade affirms not only a breakthrough innovation, but also the clinical backing and consumer relevance that distinguish future-shaping brands.
Clinically Validated, Biology-Aligned
NOTOXMD is the first natural wrinkle-reduction system independently validated in registered clinical trials (A.N.Z.C.T.R.). Instead of working against the skin, the brand’s biology-aligned philosophy supports the skin’s own recovery blueprint, underpinned by its guiding ethos: Under the Skin. The Science Within.
Dr Sharad, Founder and Master Formulator of NOTOXMD: “Thank you for the acknowledgement, I am humbled. This honour belongs to the science and the team behind NOTOXMD. We’ll continue being guided by data—and what skin is telling us.”
Charlotte Wills, Chief Executive Officer, NOTOXMD: “Skin Anarchy’s Top Picks Innovation award is a validation of our uncompromising approach, scientific rigour, not hype. /skin-line™ technology aligns with how skin naturally repairs, so results look credible and feel comfortable. We’ll continue to invest in independent validation, transparent testing, and responsible claims, ensuring every product we release earns its place on our customers’ shelves.”
About us:
The award-winning range is available now at www.notoxmd.com.
Contact details:
For further information or media enquiries, please contact: Alex Fengitis | [email protected].
